Navigation Links
Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA598
Date:6/2/2008

ys cannot provide any assurances that ANA598 and ANA773 will not have unforeseen safety issues, will have favorable results in future clinical trials or will receive regulatory approval. In addition, Anadys' results may be affected by risks related to competition from other biotechnology and pharmaceutical companies, its effectiveness at managing its financial resources, its ability to successfully develop and market products, difficulties or delays in its preclinical studies or clinical trials, difficulties or delays in manufacturing its clinical trials materials, the scope and validity of patent protection for its products, regulatory developments involving future products and its ability to obtain additional funding to support its operations. Risk factors that may cause actual results to differ are more fully discussed in Anadys' SEC filings, including Anadys' Form 10-K for the year ended December 31, 2007 and Anadys' Form 10-Q for the quarter ended March 31, 2008. All forward-looking statements are qualified in their entirety by this cautionary statement. Anadys is providing this information as of this date and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.


'/>"/>
SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
2. Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection
3. Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research
4. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
7. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
8. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
9. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
10. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
11. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... Aug. 29, 2014 Does your doctor know what ... doctors have recommended marijuana to the over 112,000 currently registered ... the majority of the other roughly 20,300+ active physicians listed ... little about it – even though a poll in February ... say they have tried it. "With marijuana ...
(Date:8/29/2014)... 2014 Diseases largely eradicated in ... returning. Measles was declared eliminated in 2000, yet the ... August 15—the highest incidence in 20 years. In July, ... whooping cough a problem of "epidemic proportions." ... dying from these preventable diseases—in part because some parents ...
(Date:8/29/2014)... UNION CITY, Calif. , Aug. 29, 2014 /PRNewswire/ ... products company manufacturing point-of-care blood instrumentation and consumables to ... Clint Severson , Chairman and Chief Executive Officer, ... Annual Best Ideas Conference 2014 on Tuesday, September 9, ... held at the Omni Berkshire Place Hotel in ...
Breaking Medicine Technology:Medical Rules Marijuana Sales in Colorado But Most Doctors Still in the Dark 2Medical Rules Marijuana Sales in Colorado But Most Doctors Still in the Dark 3Medical Rules Marijuana Sales in Colorado But Most Doctors Still in the Dark 4Vaccines at the Crossroads: Outbreaks On the Rise Across America 2Vaccines at the Crossroads: Outbreaks On the Rise Across America 3Abaxis, Inc. to Present at CL King's 12th Annual Best Ideas Conference 2014 2
... Tenn., April 10 Leading RSV,investigator Dr. John DeVincenzo ... disease that causes bronchiolitis and pneumonia,according to the Centers ... the leading cause of hospitalization of infants in the ... in this age group., DeVincenzo is using the ...
... and drug development and clinical trial, ... BEDMINSTER, N.J., April 9, 2008 Clinsys ... research,organization (CRO), today introduced its Therapeutically-aligned Program,Strategists ... and execution,of clinical trials. The TPS teams ...
Cached Medicine Technology:RSV Researcher Makes Gains in Finding Treatments 2Clinsys(R) TPS Teams Provide Comprehensive Clinical Development Plans 2Clinsys(R) TPS Teams Provide Comprehensive Clinical Development Plans 3
(Date:9/1/2014)... regular family meals may help protect teens from the ... suggests. Online abuse can lead to depression, anxiety ... five adolescents experience cyberbullying," Frank Elgar, a professor at ... University in Montreal, said in a university news release. ... and abuse are difficult for parents and educators to ...
(Date:9/1/2014)... HealthDay Reporter SATURDAY, Aug. ... an experimental drug was more effective than standard treatment ... According to the study authors, the trial was ... new drug, dubbed LCZ696. In the trial, ... (Vasotec), either died or were hospitalized due to heart ...
(Date:9/1/2014)... 2014 Currently, scientists continue to ... for Alzheimer's disease (AD), which reflects their poor ... the diagnosis of the disease, especially in its ... diagnostic tests. In 2014, after decades that ... in the medicine world, there are still no ...
(Date:9/1/2014)... The B-cell non-Hodgkin’s Lymphoma (NHL) treatment market ... (the US, France, Italy, Germany, Spain and the UK), ... 2018. , The competitive landscape in the B-cell NHL ... the UK is poised to undergo a dramatic shift ... largest B-cell NHL indications, which includes Diffuse Large B-Cell ...
(Date:9/1/2014)... 2014 As well as having completed ... currently pursuing counselor certification in Louisiana. , ... CPI training program as well as the Counselor ... both personally and professionally. I am not only ... able to do so. As a Non Violent ...
Breaking Medicine News(10 mins):Health News:Family Meals May Defuse Cyberbullying's Impact, Study Says 2Health News:Drug Gives 'New Hope' Against Heart Failure, Expert Says 2Health News:Drug Gives 'New Hope' Against Heart Failure, Expert Says 3Health News:Early Stage Minimally Invasive Candidate AD Biomarkers Reviewed in New Study by Biopharm Reports Available at MarketPublishers.com 2Health News:Early Stage Minimally Invasive Candidate AD Biomarkers Reviewed in New Study by Biopharm Reports Available at MarketPublishers.com 3Health News:B-cell Non-Hodgkin Lymphoma Treatment Market Value worth $5.4 Billion by 2018 Says a New Report Available at MarketOptimizer.org 2Health News:B-cell Non-Hodgkin Lymphoma Treatment Market Value worth $5.4 Billion by 2018 Says a New Report Available at MarketOptimizer.org 3Health News:B-cell Non-Hodgkin Lymphoma Treatment Market Value worth $5.4 Billion by 2018 Says a New Report Available at MarketOptimizer.org 4Health News:Narconon Louisiana Announces New Certifications For Staff 2
... Medical Corporation,(CRM:TSX-V) announced today that it has opened a ... Center is the Company,s first in the,state of New ... targeted for,expansion. The opening of this location represents the ... number of Centers to 14., According to the ...
... (IDF) BRIDGES translational research grant program will fund a ... for people at high-risk for getting type 2 diabetes ... develop a healthy lifestyle. , The National Hospital of ... Vietnam. Using diabetes risks questionnaires (1) , the investigators ...
... Gerson Lehrman Group, the world,s,leading marketplace for expertise, ... devoted to providing patients with the,medication information they ... personalized iGuard Risk Ratings, iGuard Safety Alerts,and a ... other registered,users who also want to get informed, ...
... is a chief reason that,patients seek medical attention; ... Physicians must be able to determine which opioid,treatment ... To make clinicians aware of the importance ... Current Clinical Practice and The,Journal of Family Practice: ...
... help breast cancer patients and menopausal women, study finds ... of a local anesthetic into the nerves of the ... long-term relief from hot flashes and sleep deprivation, a ... treatment for breast cancer, especially among women taking anti-estrogen ...
... INC. (Nasdaq:,PDEX) invites shareholders and investors to listen to ... financial results, and a discussion,of the outlook for the ... broadcast live over the Internet on,Thursday, May 15, 2008 ... by,visiting the Company,s website at http://www.pro-dex.com . Mark ...
Cached Medicine News:Health News:CRH Medical Corporation opens Center in New York 2Health News:International Diabetes Federation gives grant to diabetes screening & prevention program in Vietnam 2Health News:Gerson Lehrman Group and iGuard, Inc. Partner to Offer Patients a Voice in Healthcare Industry Decisions 2Health News:Gerson Lehrman Group and iGuard, Inc. Partner to Offer Patients a Voice in Healthcare Industry Decisions 3Health News:Treat Your Patients' Pain Effectively 2Health News:Hot Flashes Reduced by Neck Injection 2Health News:Hot Flashes Reduced by Neck Injection 3Health News:Pro-Dex, Inc. Announces Fiscal 2008 Third Quarter Financial Results Conference Call and Webcast 2
Indications For Usage: ,Used to automatically maintain a low intracuff pressure during long-term intubations....
Indications For Usage: ,Microlaryngeal surgery....
... Indications For Usage: ... ,The monitoring lumen is ... of tracheal gases especially end-tidal ... pressure. , Introducing medication. ...
... onset of VAP. (Valles J, Artigas A, ... subglottic secretions in preventing ventilator-associated pneumonia. Ann ... Auboyer C, Jospe R, et al: Prevention ... role of mechanical subglottic secretions drainage and ...
Medicine Products: